利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

74 条记录 (耗时 0.061 秒)

    Sustained release intraocular implants and methods for treating ocular neuropathies
    2.
    发明授权
    Sustained release intraocular implants and methods for treating ocular neuropathies 有权
    持续释放眼内植入物和治疗眼神经病变的方法

    公开(公告)号：US08715709B2

    公开(公告)日：2014-05-06

    申请号：US12955630

    申请日：2010-11-29

    申请人： Glenn T. Huang ,  Thierry Nivaggioli

    发明人： Glenn T. Huang ,  Thierry Nivaggioli

    IPC分类号： A61K31/5377 ,  A61F2/14 ,  A61P27/02

    CPC分类号： A61K9/0051 ,  A61K31/5377

    摘要： Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta adrenergic receptor antagonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular neuropathies, for example, various forms of glaucoma.

    摘要翻译： 生物相容性眼内植入物包括β-肾上腺素能受体拮抗剂和与β-肾上腺素能受体拮抗剂相关的聚合物，以促进β肾上腺素能受体拮抗剂延长一段时间的眼睛释放。 β肾上腺素能受体拮抗剂可以与可生物降解的聚合物基质例如两种可生物降解聚合物的基质相关联。 植入物可以放置在眼睛中以治疗一种或多种眼部病症，例如眼部神经病，例如各种形式的青光眼。

    MTOR PATHWAY INHIBITORS FOR TREATING OCULAR DISORDERS
    5.
    发明申请
    MTOR PATHWAY INHIBITORS FOR TREATING OCULAR DISORDERS 审中-公开
    MTOR途径抑制剂治疗恶病质

    公开(公告)号：US20120114637A1

    公开(公告)日：2012-05-10

    申请号：US13265530

    申请日：2010-05-04

    申请人： Thierry Nivaggioli ,  David A. Weber ,  Philippe JM Dor ,  Philip Reilly

    发明人： Thierry Nivaggioli ,  David A. Weber ,  Philippe JM Dor ,  Philip Reilly

    IPC分类号： A61K31/436 ,  A61K31/12 ,  A61K31/192 ,  A61K31/5377 ,  A61K31/409 ,  A61K31/58 ,  A61K31/4545 ,  A61K31/675 ,  A61P27/02 ,  A61K39/395 ,  A61K31/4745 ,  A61K31/404

    CPC分类号： A61K31/573 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/436 ,  A61K31/506 ,  A61K31/519

    摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are ophthalmic formulations that deliver a variety of therapeutic agents, including but not limited to rapamycin (sirolimus), analogs thereof (rapalogs) or other mTOR inhibitors, to a subject for an extended period of time. The ophthalmic formulations may be placed in an aqueous medium of a subject, including but not limited to intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer a therapeutic agent to treat or prevent age-related macular degeneration, macular edema, diabetic retinopathy, uveitis, dry eye, or a hyperpermeability disease in a subject.

    摘要翻译： 包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。 本文描述的是眼科制剂，其向受试者递送多种治疗剂，包括但不限于雷帕霉素（西罗莫司），其类似物（rapalog）或其他mTOR抑制剂）延长时间。 眼用制剂可以放置在受试者的水性介质中，包括但不限于眼内或眼周内给药或靠近受试者待治疗的疾病或病症的部位放置。 可以使用一种治疗剂来治疗或预防受试者中年龄相关性黄斑变性，黄斑水肿，糖尿病性视网膜病变，葡萄膜炎，干眼症或高渗透性疾病的方法。